Safety, pharmacokinetics and pharmacodynamics of an original glycoprotein IIb/IIIa inhibitor in healthy volunteers: results of the clinical trial
Aim. To study the tolerability, safety, pharmacokinetics (PK) and pharmacodynamics of single intravenous infusions of Angipur in healthy male volunteers.Material and methods. The Phase I trial included 20 healthy male volunteers (mean age, 30,8±7,7 years; mean body weight, 77,4±12,1 kg). Angipur (0,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2022-03-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3033 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250307862691840 |
|---|---|
| author | S. B. Fitilev Yu. F. Glukhov S. V. Lukyanov A. V. Vozzhaev I. I. Shkrebniova V. I. Kazey I. B. Bondareva |
| author_facet | S. B. Fitilev Yu. F. Glukhov S. V. Lukyanov A. V. Vozzhaev I. I. Shkrebniova V. I. Kazey I. B. Bondareva |
| author_sort | S. B. Fitilev |
| collection | DOAJ |
| description | Aim. To study the tolerability, safety, pharmacokinetics (PK) and pharmacodynamics of single intravenous infusions of Angipur in healthy male volunteers.Material and methods. The Phase I trial included 20 healthy male volunteers (mean age, 30,8±7,7 years; mean body weight, 77,4±12,1 kg). Angipur (0,02% concentrate for solution for infusion) was administered to every subject in single doses 0,015, 0,05, 0,09 mg/kg for 3 consecutive days. Volunteers were divided in 6 groups (1, 1, 3, 5, 5, 5); every following group was recruited only after the previous one finished the study. The following were assessed: rate and severity of adverse events (AEs), key PK parameters of Angipur and its antiplatelet activity by impedance aggregometry.Results. No moderate or severe AEs, as well as no serious AEs were reported according to obtained data of clinical and laboratory monitoring of healthy subjects. Totally 6 mild AEs were registered in 4 subjects. Four AEs (mild hematological deviations and episode of nose bleed) were classified as possibly related to study drug and 1 AE (positive fecal occult blood test) — probably related. Key PK parameters of Angipur in single intravenous doses 0,015, 0,05 и 0,09 mg/kg were determined as follows: Cmax — 12,44±4,689, 46,10±14,295, 92,48±33,896 ng/ml; Vd — 304,01±55,300, 299,67±64,244, 252,96±47,790 l; T1/2 — 6,72±1,290, 6,84±2,341, 6,06±2,287 h; Cl — 32,19±6,919, 32,29±8,357, 31,55±10,113 l/h, respectively. Dose proportionality (linear PK) for parameters Cmax, AUC0-t and AUC0-∞ was established. Dose-dependent reduction of ADP-induced platelet aggregation degree and area under curve was revealed at period of 15 min to 2-4 h after Angipur infusion in doses 0,05 and 0,09 mg/kg.Conclusion. Results of phase I clinical trial demonstrated good tolerability of single intravenous infusions of Angipur (0,015, 0,05 и 0,09 mg/kg) in healthy subjects. We determined key PK parameters and indicated dose-dependent antiplatelet activity of Angipur. |
| format | Article |
| id | doaj-art-57e93bdde320438eaa2e3187eda7f1ee |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2022-03-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-57e93bdde320438eaa2e3187eda7f1ee2025-08-20T03:57:18Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252022-03-0121310.15829/1728-8800-2022-30332440Safety, pharmacokinetics and pharmacodynamics of an original glycoprotein IIb/IIIa inhibitor in healthy volunteers: results of the clinical trialS. B. Fitilev0Yu. F. Glukhov1S. V. Lukyanov2A. V. Vozzhaev3I. I. Shkrebniova4V. I. Kazey5I. B. Bondareva6Peoples’ Friendship University of RussiaLLC ELTA CompanyLLC ELTA CompanyPeoples’ Friendship University of RussiaPeoples’ Friendship University of RussiaLLC Exacte LabsPeoples’ Friendship University of RussiaAim. To study the tolerability, safety, pharmacokinetics (PK) and pharmacodynamics of single intravenous infusions of Angipur in healthy male volunteers.Material and methods. The Phase I trial included 20 healthy male volunteers (mean age, 30,8±7,7 years; mean body weight, 77,4±12,1 kg). Angipur (0,02% concentrate for solution for infusion) was administered to every subject in single doses 0,015, 0,05, 0,09 mg/kg for 3 consecutive days. Volunteers were divided in 6 groups (1, 1, 3, 5, 5, 5); every following group was recruited only after the previous one finished the study. The following were assessed: rate and severity of adverse events (AEs), key PK parameters of Angipur and its antiplatelet activity by impedance aggregometry.Results. No moderate or severe AEs, as well as no serious AEs were reported according to obtained data of clinical and laboratory monitoring of healthy subjects. Totally 6 mild AEs were registered in 4 subjects. Four AEs (mild hematological deviations and episode of nose bleed) were classified as possibly related to study drug and 1 AE (positive fecal occult blood test) — probably related. Key PK parameters of Angipur in single intravenous doses 0,015, 0,05 и 0,09 mg/kg were determined as follows: Cmax — 12,44±4,689, 46,10±14,295, 92,48±33,896 ng/ml; Vd — 304,01±55,300, 299,67±64,244, 252,96±47,790 l; T1/2 — 6,72±1,290, 6,84±2,341, 6,06±2,287 h; Cl — 32,19±6,919, 32,29±8,357, 31,55±10,113 l/h, respectively. Dose proportionality (linear PK) for parameters Cmax, AUC0-t and AUC0-∞ was established. Dose-dependent reduction of ADP-induced platelet aggregation degree and area under curve was revealed at period of 15 min to 2-4 h after Angipur infusion in doses 0,05 and 0,09 mg/kg.Conclusion. Results of phase I clinical trial demonstrated good tolerability of single intravenous infusions of Angipur (0,015, 0,05 и 0,09 mg/kg) in healthy subjects. We determined key PK parameters and indicated dose-dependent antiplatelet activity of Angipur.https://cardiovascular.elpub.ru/jour/article/view/3033angipur3-methyl-8-(piperazin-1-yl)-7-(thietan-3-yl)-1- ethyl-1h-purine-2,6(3h,7h)-dione hydrochloridehealthy subjectspharmacokineticssafetyimpedance aggregometry |
| spellingShingle | S. B. Fitilev Yu. F. Glukhov S. V. Lukyanov A. V. Vozzhaev I. I. Shkrebniova V. I. Kazey I. B. Bondareva Safety, pharmacokinetics and pharmacodynamics of an original glycoprotein IIb/IIIa inhibitor in healthy volunteers: results of the clinical trial Кардиоваскулярная терапия и профилактика angipur 3-methyl-8-(piperazin-1-yl)-7-(thietan-3-yl)-1- ethyl-1h-purine-2,6(3h,7h)-dione hydrochloride healthy subjects pharmacokinetics safety impedance aggregometry |
| title | Safety, pharmacokinetics and pharmacodynamics of an original glycoprotein IIb/IIIa inhibitor in healthy volunteers: results of the clinical trial |
| title_full | Safety, pharmacokinetics and pharmacodynamics of an original glycoprotein IIb/IIIa inhibitor in healthy volunteers: results of the clinical trial |
| title_fullStr | Safety, pharmacokinetics and pharmacodynamics of an original glycoprotein IIb/IIIa inhibitor in healthy volunteers: results of the clinical trial |
| title_full_unstemmed | Safety, pharmacokinetics and pharmacodynamics of an original glycoprotein IIb/IIIa inhibitor in healthy volunteers: results of the clinical trial |
| title_short | Safety, pharmacokinetics and pharmacodynamics of an original glycoprotein IIb/IIIa inhibitor in healthy volunteers: results of the clinical trial |
| title_sort | safety pharmacokinetics and pharmacodynamics of an original glycoprotein iib iiia inhibitor in healthy volunteers results of the clinical trial |
| topic | angipur 3-methyl-8-(piperazin-1-yl)-7-(thietan-3-yl)-1- ethyl-1h-purine-2,6(3h,7h)-dione hydrochloride healthy subjects pharmacokinetics safety impedance aggregometry |
| url | https://cardiovascular.elpub.ru/jour/article/view/3033 |
| work_keys_str_mv | AT sbfitilev safetypharmacokineticsandpharmacodynamicsofanoriginalglycoproteiniibiiiainhibitorinhealthyvolunteersresultsoftheclinicaltrial AT yufglukhov safetypharmacokineticsandpharmacodynamicsofanoriginalglycoproteiniibiiiainhibitorinhealthyvolunteersresultsoftheclinicaltrial AT svlukyanov safetypharmacokineticsandpharmacodynamicsofanoriginalglycoproteiniibiiiainhibitorinhealthyvolunteersresultsoftheclinicaltrial AT avvozzhaev safetypharmacokineticsandpharmacodynamicsofanoriginalglycoproteiniibiiiainhibitorinhealthyvolunteersresultsoftheclinicaltrial AT iishkrebniova safetypharmacokineticsandpharmacodynamicsofanoriginalglycoproteiniibiiiainhibitorinhealthyvolunteersresultsoftheclinicaltrial AT vikazey safetypharmacokineticsandpharmacodynamicsofanoriginalglycoproteiniibiiiainhibitorinhealthyvolunteersresultsoftheclinicaltrial AT ibbondareva safetypharmacokineticsandpharmacodynamicsofanoriginalglycoproteiniibiiiainhibitorinhealthyvolunteersresultsoftheclinicaltrial |